Physician profile
Hannah Cisson
NPI 1144958547
$1,092.97
in general payments reported to CMS, 2019-2025
23 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $234 · 2023: $374 · 2024: $366 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $218.87 | 2022-2025 | Farxiga, Lokelma |
| Exact Sciences Corporation | $118.64 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $70.22 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $69.84 | 2024 | Quviviq |
| Lilly USA, LLC | $66.16 | 2023 | Mounjaro, Jardiance, Emgality |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.47 | 2025 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $49.68 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $48.44 | 2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $47.30 | 2024 | Repatha |
| Hologic Sales and Service, LLC | $44.17 | 2024-2025 | Aptima |
| Abbvie INC. | $40.33 | 2023-2024 | |
| Glaxosmithkline, LLC. | $38.86 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Kiniksa Pharmaceuticals International, Plc | $36.32 | 2024 | Arcalyst |
| Lundbeck LLC | $22.66 | 2023 | Vyepti |
| Pfizer INC. | $21.45 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $20.36 | 2024 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $19.66 | 2023 | Glassia |
| Lexicon Pharmaceuticals, INC. | $18.60 | 2024 | |
| Merck Sharp & Dohme LLC | $17.98 | 2024 | Verquvo |
| Seqirus USA INC | $17.92 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.35 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Cisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.